Veliparib

What is Veliparib?

Veliparib is an investigational oral poly(ADP-ribose) polymerase (PARP) inhibitor. Developed by AbbVie, it represents a significant area of research in the field of oncology, particularly for its potential to enhance the efficacy of chemotherapy and radiation therapy in various cancer types. Unlike some other PARP inhibitors that have received regulatory approval for specific indications, Veliparib remains primarily under investigation in numerous clinical trials worldwide. It is designed to target specific pathways within cancer cells, aiming to disrupt their ability to repair damaged DNA, thereby leading to cell death.

How Does it Work?

The mechanism of action for Veliparib PARP inhibitor revolves around its ability to selectively inhibit PARP-1 and PARP-2 enzymes. These enzymes play a crucial role in the cell's DNA repair machinery, particularly in repairing single-strand breaks. When PARP enzymes are inhibited, single-strand breaks can accumulate and transform into more severe double-strand breaks, which are harder for cancer cells to repair.

Furthermore, Veliparib is thought to exert a 'PARP trapping' effect, where the drug binds to PARP enzymes on DNA, preventing their release and hindering the repair process even further. This mechanism is particularly effective in cancer cells that already have defects in other major DNA repair pathways, such as homologous recombination deficiency (HRD), often seen in cells with mutations in the BRCA mutations genes (BRCA1/2). This concept is known as synthetic lethality, where the combination of two non-lethal events (PARP inhibition and pre-existing HRD) becomes lethal to the cancer cell, while sparing healthy cells that have intact DNA repair mechanisms.

Medical Uses

As an investigational agent, Veliparib has been extensively studied across a broad spectrum of cancers, often in combination with other established treatments. Its primary focus is on cancers where DNA repair pathways are compromised or where it can sensitize cancer cells to DNA-damaging therapies. Key areas of investigation include:

• Breast Cancer: Particularly in triple-negative breast cancer (TNBC) and in patients with BRCA1/2 mutations. Clinical trials have explored its use alongside chemotherapy regimens like carboplatin and paclitaxel.
• Ovarian Cancer: Similar to breast cancer, Veliparib has been investigated for its role in ovarian cancer, especially in patients with BRCA mutations or platinum-sensitive disease, often in combination with chemotherapy.
• Non-Small Cell Lung Cancer (NSCLC): Studies have evaluated its potential to enhance the effects of chemotherapy and radiation in advanced NSCLC.
• Melanoma: Research has explored Veliparib in combination with temozolomide for melanoma.
• Pancreatic Cancer: Investigated in combination with chemotherapy for advanced pancreatic cancer.
• Other Solid Tumors: Veliparib has also been studied in glioblastoma, prostate cancer, and other malignancies, always with the aim of exploiting its DNA repair inhibition properties.

It is crucial to remember that these are investigational uses, and Veliparib is not broadly approved for these indications as a standalone treatment.

Dosage

Since Veliparib is an investigational drug, there is no standardized, commercially approved dosage. The dosage and administration schedule for Veliparib PARP inhibitor vary significantly depending on the specific clinical trial protocol, the type of cancer being treated, the combination therapy used, and the patient's individual characteristics and tolerance to the drug. Typically, Veliparib is administered orally, often twice daily. Doses observed in clinical trials have ranged from 50 mg twice daily to up to 400 mg twice daily, sometimes in cycles corresponding to chemotherapy administration.

Patients receiving Veliparib in a clinical trial setting are under strict medical supervision, with dosages adjusted based on treatment response and the management of side effects. It is imperative that patients do not attempt to self-medicate or obtain Veliparib outside of a controlled clinical trial environment.

Side Effects

Like all pharmaceutical agents, Veliparib can cause side effects. These are often compounded by the concurrent administration of chemotherapy or radiation, which themselves have significant adverse event profiles. Common side effects observed in clinical trials with Veliparib include:

• Myelosuppression: This is a common class effect of PARP inhibitors and can manifest as anemia (low red blood cell count), neutropenia (low white blood cell count, increasing infection risk), and thrombocytopenia (low platelet count, increasing bleeding risk).
• Gastrointestinal Issues: Nausea, vomiting, diarrhea, and constipation are frequently reported.
• Fatigue: Patients may experience significant tiredness and lack of energy.
• Alopecia: Hair loss can occur, particularly when combined with certain chemotherapies.
• Other: Less common side effects can include headache, dizziness, and changes in liver function tests.

Close monitoring by healthcare professionals is essential to manage these side effects effectively and ensure patient safety during treatment with this antineoplastic agent.

Drug Interactions

Understanding potential drug interactions is critical when considering any investigational therapy like Veliparib PARP inhibitor. Veliparib is metabolized by the cytochrome P450 3A4 (CYP3A4) enzyme system. Therefore, co-administration with other drugs that affect CYP3A4 activity can alter Veliparib plasma concentrations:

• CYP3A4 Inhibitors: Strong inhibitors of CYP3A4 (e.g., ketoconazole, clarithromycin, grapefruit juice) can increase Veliparib exposure, potentially leading to increased side effects.
• CYP3A4 Inducers: Strong inducers of CYP3A4 (e.g., rifampin, carbamazepine, St. John's Wort) can decrease Veliparib exposure, potentially reducing its efficacy.
• Myelosuppressive Agents: Given Veliparib's myelosuppressive potential, concurrent use with other agents known to cause bone marrow suppression (e.g., certain chemotherapies) may lead to additive toxicity and require careful dose adjustments.
• Agents Affecting DNA Repair: Other drugs that impact DNA repair pathways could theoretically interact, though specific interactions are often assessed within trial protocols.

Patients should always inform their healthcare providers about all medications, supplements, and herbal products they are taking to avoid potentially harmful interactions.

FAQ

Is Veliparib an approved drug?

No, Veliparib is currently an investigational drug and is not approved by regulatory bodies like the FDA for commercial use outside of clinical trials.

What types of cancer is Veliparib being studied for?

It is being studied for a wide range of cancers, including breast, ovarian, non-small cell lung, pancreatic, and melanoma, often in combination with other therapies.

How is Veliparib administered?

Veliparib is typically administered orally, often twice daily, as part of a specific clinical trial protocol.

What is a PARP inhibitor?

A PARP inhibitor is a type of targeted therapy that blocks the activity of poly(ADP-ribose) polymerase (PARP) enzymes, which are involved in DNA repair. This action helps to kill cancer cells, especially those with pre-existing DNA repair defects.

Can Veliparib be used as a standalone treatment?

Most clinical trials for Veliparib investigate its use in combination with chemotherapy or radiation, rather than as a standalone agent, to enhance the effectiveness of these treatments.

Products containing Veliparib are available through trusted online pharmacies. You can browse Veliparib-based medications at ShipperVIP or Medicenter.

Summary

Veliparib represents a significant and promising investigational agent in the fight against cancer. As a Veliparib PARP inhibitor, it targets critical DNA repair pathways within cancer cells, aiming to induce synthetic lethality when combined with other DNA-damaging therapies. Its potential to enhance the efficacy of chemotherapy and radiation, particularly in cancers with homologous recombination deficiencies like those with BRCA mutations, makes it a valuable subject of ongoing research. While it has not yet received broad regulatory approval, the numerous clinical trials exploring its uses highlight its potential future role as an important antineoplastic agent in oncology. Continued research and careful patient selection will be key to fully realizing its therapeutic benefits.